Abstract:Background:Non-small cell lung cancer (NSCLC) frequently metastasizes to bone, leading to poor prognosis. Siglec15 has been identified as a newly discovered immune checkpoint and exists in a variety of tumors. However, the expression and function of Siglec15 in NSCLC and bone metastasis remains largely unclear.Methods:Siglec15 expression in NSCLC and the correlation between Siglec15 expression and the clinicopathological factors of patients with NSCLC were analyzed using The Cancer Genome Atlas (TCGA) dataset. Correlation analysis between Siglec15 and bone metastasis-related genes expression was based on the Molecular Signatures Database (MSigDB). Western blotting and immunohistochemistry were applied to detect Siglec15 expression in NSCLC and spinal metastasis. Human A549 and mouse CMT167 cells were transfected with Siglec15 siRNA to investigate its biological functions in NSCLC proliferation, migration, and invasion. The immune-related signaling pathways and correlations between Siglec15 and tumor-infiltrating immune cells and different immune checkpoints in the NSCLC tumor microenvironment (TME) were analyzed using Estimating Relative Subsets of RNA Transcripts (CIBERSORT) and gene set enrichment analysis (GSEA). To demonstrate Siglec15 in NSCLC cell-mediated T cell suppression and investigate the potential mechanism of Siglec15 silencing in antitumor immunity, we used a T cell killing assay in vitro and the high‑throughput sequencing approach.Results:Siglec15 expression was positively associated with the tumor stage and lymph node metastasis, and was markedly up-regulated in NSCLC bone metastasis. Functionally, Siglec15 knockdown inhibited the proliferation, migration, and invasion of NSCLC cells (A549 and CMT167 cell lines). A total of eight kinds of tumor-infiltrating immune cells were found to have a strong association with the Siglec15 expression in NSCLC cases. The expression of previously discovered immune checkpoints was higher in the high Siglec15 expression NSCLC group. Furthermore, an in vitro T cell killing assay showed that the down-regulation of Siglec15 in tumor cells could enhance the antitumor immune responses of CD8+ T cells. High‑throughput sequencing revealed the potential molecular mechanisms underlying the Siglec15-mediated immunosuppression effect of tumor cells on immune cells.Conclusions:Siglec15 may be involved in the pathogenesis of spinal metastasis in NSCLC and provide a new potential therapeutic target for the treatment of NSCLC and bone metastasis.

Siglec‐15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44

Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells

Extracellular Serglycin Upregulates the CD44 Receptor in an Autocrine Manner to Maintain Self-Renewal in Nasopharyngeal Carcinoma Cells by Reciprocally Activating the MAPK/β-catenin Axis

SIGLEC15, Negatively Correlated with PD-L1 in HCC, Could Induce CD8+ T Cell Apoptosis to Promote Immune Evasion

CD44 Potentiates Hepatocellular Carcinoma Migration and Extrahepatic Metastases Via the AKT/ERK Signaling CXCR4 Axis.

Siglec15 Promotes the Migration of Thyroid Carcinoma Cells by Enhancing the EGFR Protein Stability.

Siglec15 Facilitates the Progression of Non-Small Cell Lung Cancer and is Correlated with Spinal Metastasis.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma

Siglec15 in blood system diseases: from bench to bedside

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

N-glycosylation of Siglec-15 Decreases Its Lysosome-Dependent Degradation and Promotes Its Transportation to the Cell Membrane.

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer

The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma

Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial–mesenchymal transition and Beclin-1/ATG14 pathway

N-glycosylation at N57/100/110 affects CD44s localization, function and stability in hepatocellular carcinoma

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer

Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma